Fairfield, Bush & Co’s Organon & Co OGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-8,956
Closed -$129K 358
2023
Q4
$129K Sell
8,956
-6,412
-42% -$87.2K 0.08% 132
2023
Q3
$267K Buy
15,368
+6
+0% +$125 0.17% 94
2023
Q2
$320K Buy
15,362
+6
+0% +$130 0.09% 124
2023
Q1
$361K Sell
15,356
-555
-3% -$14.9K 0.13% 111
2022
Q4
$444K Sell
15,911
-3,013
-16% -$77K 0.29% 74
2022
Q3
$443K Buy
18,924
+882
+5% +$26.6K 0.31% 71
2022
Q2
$609K Buy
18,042
+1,740
+11% +$60.9K 0.36% 56
2022
Q1
$569K Buy
16,302
+481
+3% +$16.4K 0.29% 74
2021
Q4
$482K Buy
15,821
+77
+0.5% +$2.51K 0.23% 78
2021
Q3
$516K Buy
+15,744
New +$504K 0.17% 110

Other funds holding OGN

Fairfield, Bush & Co's OGN Position: Q1 2024 in Review

Fairfield, Bush & Co sold out of Organon & Co (OGN) in Q1 2024, closing a stake of 8,956 shares — an estimated $129K sold.

Fairfield, Bush & Co first reported a position in OGN in Q3 2021 and held it in 10 quarters. The position peaked at $609K in Q2 2022. 720 funds tracked by Wall St. Rank hold OGN as of Q1 2024.

  • Fairfield, Bush & Co reported no remaining Organon & Co position as of Q1 2024 after selling out during the quarter.
  • Fairfield, Bush & Co sold 8,956 Organon & Co shares in Q1 2024, an estimated $129K.
  • Fairfield, Bush & Co first reported a position in Organon & Co in Q3 2021 and held it in 10 quarters.
  • Fairfield, Bush & Co's Organon & Co position peaked at $609K in Q2 2022.
  • 720 funds tracked by Wall St. Rank held Organon & Co as of Q1 2024.

Based on Fairfield, Bush & Co's 13F filing for Q1 2024, filed 15 May 2024.